SINE-venetoclax combination inhibits tumor growth and prolongs survival in DLBCL mouse xenograft models. (A) A DoHH-2 xenograft model was used to test the in vivo efficacy of treatment with eltanexor, venetoclax, or eltanexor-venetoclax combined compared with vehicle control. The data represent the mean of 6 to 8 mice per cohort ± standard error of the mean (SEM). (B) Kaplan-Meier survival of mouse cohorts (n = 7-8 mice each), indicating median survival for mice treated with vehicle (16 days), eltanexor (26 days), venetoclax (26 days), or eltanexor-venetoclax combined (37 days). (C) Representative immunohistochemical staining of tumor sections for expression of cleaved caspase 3, ApopTag, p53, p21, and BCL6 from DoHH-2 xenograft mice in panel A. Scale bar, 20 µm. Histology images were acquired with an Aperio AT Turbo scanner at 20× magnification. (D) A Toledo xenograft model was allowed to grow to an average volume of 800 mm³ before testing the in vivo efficacy of treatment with selinexor, venetoclax, or selinexor-venetoclax combined compared with vehicle. The data represent the mean of 10 mice per cohort ± SEM. (E) The percentage change of the vehicle and 3 treatment groups on day 12 was normalized to the baseline measurement of each group on day 1 of treatment. The data represent the mean of 10 mice per cohort ± SEM. *P < .05; **P < .01; ***P < .001; ****P < .0001.